Joanne Beck
Directeur/Membre du Conseil chez ASTRIA THERAPEUTICS, INC.
Fortune : - $ au 30/04/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Robert Ford | M | 50 | 9 ans | |
| Robert Funck | M | 62 | 37 ans | |
| Jill Milne | M | 56 | 16 ans | |
| Bobby Gaspar | M | 60 |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 9 ans |
| Charles Rowland | M | 65 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 ans |
| Marc Dunoyer | M | 71 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 ans |
| Kathryn Collins | F | - | 25 ans | |
| David Elkins | M | 55 | 6 ans | |
| Andrea Matthews | F | 42 | 10 ans | |
| Frank Thomas | M | 54 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 ans |
| Jon Ellis | M | 57 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 ans |
| Noah Clauser | M | 51 | 13 ans | |
| Simone Song | F | 59 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 7 ans |
| James Geraghty | M | 69 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 ans |
| Hubert Allen | M | 58 | 18 ans | |
| Ken Bate | M | 73 | 10 ans | |
| John McCoy | M | 54 | 6 ans | |
| Scott House | M | - | 34 ans | |
| Alicia Secor | F | 62 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 ans |
| Sally Blount | M | 62 | 13 ans | |
| Katherine Reynolds Kelly | F | 48 | 5 ans | |
| Claire Babineaux-Fontenot | F | 59 | 2 ans | |
| P. Joseph Campisi | M | - | 5 ans | |
| Paola Gonzalez | F | 52 | 3 ans | |
| Hugh Cole | M | 59 | 5 ans | |
| Darren McDew | M | 63 | 5 ans | |
| Michelle Kumbier | F | 57 | 6 ans | |
| Scott Leinenweber | M | - | 27 ans | |
| Philip Boudreau | M | 51 | 27 ans | |
| Frederick Callori | M | 56 | 3 ans | |
| Michael O'Grady | M | 58 | 1 ans | |
| Daniel Starks | M | 69 | 7 ans | |
| Rajeev Venkayya | M | - |
Aerium Therapeutics, Inc.
 Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Matt Roden | M | 53 | 5 ans | |
| Randel Woodgrift | M | 62 | 12 ans | |
| Gregg Lapointe | M | 65 | 5 ans | |
| John Stratton | M | 63 | 7 ans | |
| Michael Kishbauch | M | 75 | 8 ans | |
| Melissa Brotz | F | - | - | |
| Nancy McKinstry | F | 65 | 13 ans | |
| Jonathan Violin | M | 48 | 3 ans | |
| Mary Moreland | F | 57 | 13 ans | |
| Michael Roman | M | 64 | 3 ans | |
| Robert Alpern | M | 73 | 16 ans | |
| Otello Stampacchia | M | 55 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Andrew Komjathy | M | 61 | 5 ans | |
| Takeyoshi Yamashita | M | 62 | - | |
| Kate Dyer | F | - | 4 ans | |
| Claude Ramoni | M | - |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Karen Chayavirabood | F | - | - | |
| Lisa Earnhardt | F | 54 | 5 ans | |
| Keri McGrail | F | - | 3 ans | |
| Gene Huang | M | - | - | |
| Ann Li Lee | M | 63 | 6 ans | |
| Yasuo Fujii | M | - | - | |
| Stephen Knight | M | 63 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Michael Powell | M | 69 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Ben Harshbarger | M | 55 | 4 ans | |
| Christopher Morabito | M | 54 | 2 ans | |
| Daniel Gesua Sive Salvadori | M | - | - | |
| Jim Leffelman | M | - | - | |
| John Maraganore | M | 60 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| John M. Capek | M | 62 | 18 ans | |
| Peter Honig | M | 67 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Andrea Wainer | F | - | 27 ans | |
| Vincent Ossipow | M | 55 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Fulvio Mavilio | M | - | 2 ans | |
| Jeffrey Galik | M | - | 5 ans | |
| John Ruesch | M | - | 1 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Mark Rothera | M | 61 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom.
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | 3 ans |
| Mark Alles | M | 64 | 15 ans | |
| Deirdre Cunnane | F | 59 | 4 ans | |
| Robert Hugin | M | 69 | 19 ans | |
| Jacqualyn Fouse | M | 62 | 7 ans | |
| Jonathan Biller | M | 61 | 8 ans | |
| Nicolas Koebel | M | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 7 ans |
| Peter Kellogg | M | 67 | 5 ans | |
| Timothy J. Smith | M | - | - | |
| Scott Smith | M | 61 | 10 ans | |
| Thomas Daniel | M | 70 | 10 ans | |
| Anne Dupraz-Poiseau | M | - | 6 ans | |
| Rupert Vessey | M | 59 | 4 ans | |
| John Curnutte | M | 72 | 5 ans | |
| Thomas Perone | M | 59 | 12 ans | |
| Brendan Delaney | M | 49 | 6 ans | |
| Andrea Spezzi | M | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 ans |
| Carrie Cox | F | 66 | 10 ans | |
| Jay Backstrom | M | 69 | 11 ans | |
| Robert Hershberg | M | 61 | 5 ans | |
| Michael Friedman | M | 80 | 8 ans | |
| Michael Bonney | M | 65 | 4 ans | |
| James J. Loughlin | M | 81 | 12 ans | |
| Richard W. Barker | M | 75 | 7 ans | |
| Burt Adelman | M | 71 | 5 ans | |
| Michael D. Casey | M | 78 | 17 ans | |
| Ernest Mario | M | 85 | 12 ans | |
| Gilla Kaplan | M | 76 | 20 ans | |
| Patricia Hemingway Hall | F | 71 | 1 ans | |
| Craig T. Basson | M | - |
Boston Pharmaceuticals, Inc.
 Boston Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Boston Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that leverages a drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The company was founded by Robert Armstrong and Chris Viehbacher and is headquartered in Cambridge, MA. | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 84 | 84,85% |
| Royaume-Uni | 16 | 16,16% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Joanne Beck
- Réseau Personnel
